ArticleActa neuropathologica2026
Molecular programs in human locus coeruleus link APOE and neuromelanin to Alzheimer's vulnerability.
Article in Acta neuropathologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
The locus coeruleus (LC) is a small noradrenergic nucleus in the dorsal pons that sends widespread projections across the brain to regulate sleep, arousal, and cognition. LC neurons show early accumulation of phosphorylated tau (pTau) and are particularly vulnerable to degeneration in Alzheimer's disease (AD). AD is also associated with loss of neuromelanin (NM) pigmentation in LC neurons, and NM-sensitive neuroimaging predicts clinical severity and future disease progression. To better understand molecular vulnerability of the LC, we generated spatially resolved transcriptomics data on LC tissue sections from 33 neurotypical middle-aged human brain donors, stratified by AD risk factors including sex, African or European ancestry, and APOE haplotype (E4 risk or E2 protective allele carriers). Comparing across APOE haplotypes, we identify reduced astrocytic gene expression proximal to LC neurons in E4 carriers, in addition to ancestry-specific differences in LC gene expression. Cell-resolution in situ sequencing further demonstrated that APOE differences in LC regional gene expression were partially driven by astrocytes, with more marked haplotype effects in donors of European ancestry. Quantifying gene expression as a factor of local NM content, we find that higher APOE gene expression correlates with reduced NM, and that NM-associated genes are enriched for aging-related pathways. Using the in situ data to analyze NM content in individual LC neurons validated NM associations with expression of APOE, norepinephrine metabolism genes, and genes involved in autophagy. Together, these data suggest that AD risk factors modulate LC vulnerability via molecular processes intrinsic to both noradrenergic neurons and local astrocytes.
Indexed as
Identifiers
42726290What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.